Saphnelo (anifrolumab-fnia) - AstraZeneca
Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event? (PubMed, Dermatol Pract Concept) - Oct 11, 2026 - No abstract available 
Adverse events • Journal • Immunology • Psoriasis
http://www.ncbi.nlm.nih.gov/pubmed/42858422
 
Iacopo Ghini; Luca Bettolini; Mariateresa Rossi; Silvia Zanghì; Stefano Bighetti; Vincenzo Maione
 
Oct 11, 2026
 
Prev Next